Health care stocks still were drifting lower this afternoon, with the NYSE Health Care Index slipping 0.1% while the SPDR Health Care Select Sector ETF was down less than 0.1%.
The Nasdaq Biotechnology index also was falling 0.1%.
In company news, OncoSec Medical (ONCS) was falling 1.4%, giving back an earlier advance that followed the biotechnology company Tuesday saying it has received a US patent for its interleukin 12-based immunotherapy platform, including its lead product candidate TAVO and its proprietary EP gene delivery system. The new patent also covers the use of intratumoral electroporation of DNA encoding interleukins to treat cancer.
Axovant Gene Therapies (AXGT) dropped almost 23% after saying two of the four patients in a cohort for its AXO-Lenti-PD experimental treatment for Parkinson's disease were unable to participate in post-trial assessments, upstaging postive results from the phase II study. One of the patients refused to continue in the trial while the other patient contracted COVID-19, the company said.
To the upside, Kiniksa Pharmaceuticals (KNSA) climbed nearly 18% after reporting positive data from phase II testing of its mavrilimumab drug candidate in patients with giant cell arteritis, with the investigational antibody achieving both its primary and secondary endpoints.